Revenue segments as reported by the company.

Cardiovascular

Medical Surgical

Neuroscience

Diabetes

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general, and administrative

Amortization of intangible assets

Restructuring charges, net

Certain litigation charges, net

Other operating expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Medtronic

Medtronic Plc is a medical technology company, which engages in the development, manufacture, distribution, and sale of device-based medical therapies and services. It operates through the following segments: Cardiovascular Porrtfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment includes products for the diagnosis, treatment, and management of cardiac rhythm disorders and cardiovascular disease. The Neuroscience Portfolio is made up of cranial and spinal technologies, specialty therapies, and neuromodulation divisions. The Medical Surgical Portfolio is comprised of surgical innovations and respiratory, gastrointestinal, and renal divisions. The Diabetes Group segment offers insulin pumps, continuous glucose monitoring systems, and insulin pump consumables. The company was founded in 1949 and is headquartered in Dublin, Ireland.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Medtronic reports strong Q4 results, anticipates margin pressures for FY '24

MDT reported strong Q4 results with organic revenue growth, but anticipates margin pressures and EPS decline for FY '24. They highlighted successful FDA approvals and expressed confidence in growth opportunities.

Medtronic reports strong Q2 earnings, highlights growth opportunities

Medtronic's Q2 earnings call showcased strong financial performance, with raised full-year guidance. The company emphasized growth in key business segments and highlighted opportunities in insulin-dependent patient solutions and AI-powered solutions. Challenges include delays in PMRI spend and minimal impact of GLP-1s on the business.

Medtronic exceeds Q3 expectations, focuses on growth and transformation

Medtronic's Q3 earnings call highlighted strong performance, raised outlook, and a focus on transformation for sustainable growth. The company is strategically addressing challenges through cost reduction efforts and seizing opportunities in key markets. Medtronic remains committed to driving innovation and maximizing shareholder value.

Medtronic exceeds Q4 expectations, eyes growth in innovative healthcare

Medtronic's Q4 performance showcased strong growth in key segments, with a focus on innovation and market expansion. Despite challenges from inflation and currency impact, the company remains optimistic about future growth opportunities driven by product advancements and strategic acquisitions.

Medtronic reports robust Q1 results, eyes growth amid challenges

Medtronic's Q1 performance showcased strong revenue growth and emphasized innovation across key business segments.
While facing challenges of growth deceleration and margin expansion, the company remains focused on operational efficiencies and market fundamentals.
Opportunities lie in bariatric space growth, ongoing transformation efforts, and advancements in diabetes programs and surgical systems.
Overall, Medtronic's strategic investments in technology, pricing strategies, and procedural trends position it for continued success and market leadership.

Medtronic surpasses revenue expectations, eyes growth in key markets

Medtronic delivered strong Q2 results with revenue growth ahead of expectations and raised full-year guidance. Despite concerns about GLP-1 drugs and the SELECT trial, the company remains optimistic about growth prospects, focusing on key markets and product innovation.

Medtronic reports solid Q3 growth, focuses on innovation and profitability

Medtronic's Q3 earnings call showcased strong financial performance, international market growth, and strategic decisions to drive innovation and profitability. The company's focus on new technologies, portfolio management, and overcoming challenges highlights a path towards sustained growth and earnings leverage. With positive progress in key business segments and a commitment to future profitability, Medtronic is well-positioned for continued success.

Medtronic reports robust Q4 growth, eyes operational efficiency and China

Medtronic's Q4 2024 earnings call highlighted strong revenue growth, new product launches, and a focus on restoring earnings power. The company provided guidance for fiscal year '25, expecting organic revenue growth, operating margin expansion, and non-GAAP diluted EPS. Analyst questions centered on EPS guidance, revenue growth drivers, and operational efficiencies.

Medtronic reports solid Q1 results, raises guidance for fiscal '25

Medtronic's Q1 2025 performance reflects steady revenue growth and increased EPS, driven by strong performances in key business segments and global markets.
The company's focus on innovation, strategic partnerships, and diversified revenue streams positions it well for future growth and market expansion.
While challenges exist in maintaining growth momentum and navigating market complexities, Medtronic's raised guidance and growth expectations signal confidence in its ability to drive top-line growth and restore earnings power.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Medtronic is well-positioned to benefit from global demographic trends. The market appears to be overly rotated on short-term supply side concerns.

Medtronic Is Now Mind-Numbingly Cheap

This latest approval broadens Medtronic's scope within its Cardiovascular Diagnostics and Services wing within broader Cardiovascular business.

Medtronic (MDT) Gets FDA's 510(k) Nod for Pediatric ICM

Medtronic (MDT) reported earnings 30 days ago. What's next for the stock?

Medtronic (MDT) Down 4% Since Last Earnings Report: Can It Rebound?

Recently, Zacks.com users have been paying close attention to Medtronic (MDT). This makes it worthwhile to examine what the stock has in store.

Is Trending Stock Medtronic PLC (MDT) a Buy Now?

NEW YORK--(BUSINESS WIRE)--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Medtronic plc (“Medtronic” or the “Company”) (NYSE: MDT) and certain of its officers, on behalf of all persons and entities that purchased, or otherwise acquired Medtronic securities between June 8, 2019, and May 25, 2022, both dates inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm's site

Investor Alert: Medtronic plc (MDT) Class Action - Bronstein, Gewirtz & Grossman, LLC, A Prominent Firm, Encourages Shareholders to Actively Participate

DUBLIN , Sept. 21, 2022 /PRNewswire/ -- Medtronic plc (the "Company") (NYSE: MDT) today announced that its wholly-owned subsidiary Medtronic Global Holdings S.C.A.

Medtronic announces closing of public offering of €3.5 billion of senior notes

The LINQ II ICM is the first continuous, long-term cardiac monitor cleared by FDA for the pediatric patient population DUBLIN , Sept. 20, 2022 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced the LINQ II™ Insertable Cardiac Monitor (ICM) system is the first-and-only ICM to receive 510(k) clearance by the U.S. Food and Drug Administration (FDA) for use in pediatric patients over the age of 2 who have heart rhythm abnormalities and require long-term, continuous monitoring.

Medtronic receives FDA clearance for expanded indication of LINQ II™ insertable cardiac monitor for use in pediatric patients ages 2 and older

NEW YORK , Sept. 19, 2022 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the stock of Medtronic plc (NYSE: MDT) between June 8, 2019 and May 25, 2022, both dates inclusive (the "Class Period"), of the important November 7, 2022 lead plaintiff deadline.

ROSEN, SKILLED INVESTOR COUNSEL, Encourages Medtronic plc Investors With Losses to Secure Counsel Before Important Deadline in Securities Class Action - MDT

Long-term analysis from landmark renal denervation trial presented as Late Breaking Clinical Science, published simultaneously in The Lancet Data add to growing body of evidence supporting the durability of the Symplicity blood pressure procedure DUBLIN and BOSTON , Sept. 18, 2022 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced long-term results from the SYMPLICITY HTN-3 clinical trial.

TCT 2022: SYMPLICITY HTN-3 trial data show sustained long-term blood pressure reductions with Medtronic renal denervation procedure

New York, New York--(Newsfile Corp. - September 17, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the stock of Medtronic plc (NYSE: MDT) between June 8, 2019 and May 25, 2022, both dates inclusive (the "Class Period"), of the important November 7, 2022 lead plaintiff deadline.

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Medtronic plc Investors With Losses to Secure Counsel Before Important Deadline in Securities Class Action - MDT

DUBLIN , Sept. 15, 2022 /PRNewswire/ -- Medtronic plc (the "Company") (NYSE:MDT) announced today that its wholly-owned subsidiary, Medtronic Global Holdings S.C.A.

Medtronic announces pricing of €3.5 billion of senior notes

Medtronic plc (NYSE:MDT ) Bank of America Global Healthcare Conference 2022 September 15, 2022 9:10 AM ET Company Participants Rob ten Hoedt - Executive Vice President & President EMEA & APAC Conference Call Participants Travis Steed - Bank of America Rob ten Hoedt [Call Starts Abruptly] That is the de novo patients plus the deferred patients should all be treated, then we're going to get this increase in productivity. That happened in Spain and Italy but it didn't in France, in the UK and in Germany.

Medtronic plc (MDT) Presents at Bank of America Global Healthcare Conference 2022 (Transcript)

Los Angeles, California--(Newsfile Corp. - September 15, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Medtronic plc ("Medtronic" or "the Company") (NYSE: MDT) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Medtronic plc with Losses of $500,000 to Contact the Firm

Matthews International

M.D.C. Holdings

Dividend stocks have performed better this year than the broader market, but that is mostly because of the difference in sector allocation between dividend payers and nonpayers. Whether buying socks or stocks, to paraphrase Warren Buffett, it's usually a good idea to buy quality items on discount.

3 Cheap Dividend Stocks To Consider

Los Angeles, California--(Newsfile Corp. - September 13, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Medtronic plc ("Medtronic" or "the Company") (NYSE: MDT) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

INVESTOR ACTION ALERT: The Schall Law Firm Encourages Investors in Medtronic plc with Losses of $100,000 to Contact the Firm

NEW YORK , Sept. 13, 2022 /PRNewswire/ --  WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the stock of Medtronic plc (NYSE: MDT) between June 8, 2019 and May 25, 2022, both dates inclusive (the "Class Period").

ROSEN, LEADING INVESTOR COUNSEL, Encourages Medtronic plc Investors to Secure Counsel Before Important Deadline in Securities Class Action - MDT

NEW ORLEANS--(BUSINESS WIRE)--Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until November 7, 2022 to file lead plaintiff applications in a securities class action lawsuit against Medtronic plc (NYSE: MDT), if they purchased the Company's shares between June 8, 2019, and May 25, 2022, inclusive (the “Class Period”). This action is pending in the United States District Court for the District of Minn

MEDTRONIC SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Medtronic plc - MDT

SAN DIEGO--(BUSINESS WIRE)---- $MDT #MDT--Medtronic PLC (MDT) Had Inadequate Quality Control Systems That Delayed Approval of its MiniMed 780G Device and Caused Shareholders Financial Harm

Medtronic PLC Shareholder Update: Robbins LLP Reminds Investors a Class Action was Filed Against Medtronic PLC (MDT)

Medtronic plc (NYSE:MDT ) Morgan Stanley 20th Annual Global Healthcare Conference September 12, 2022 12:30 PM ET Company Participants Cecilia Furlong - VP, Medical Technology Equity Research Conference Call Participants Geoffrey Martha - Chairman and CEO Cecilia Furlong Good afternoon. Welcome to the first day of the Morgan Stanley Healthcare Conference.

Medtronic plc (MDT) CEO Geoffrey Martha Presents at Morgan Stanley 20th Annual Global Healthcare Conference (Transcript)

When a leading healthcare technology stock falls during a bear market it means one thing -- opportunity

Your Portfolio Could Be Missing This Stock With Monster Potential

Ra Medical Systems Inc

CARLSBAD, Calif.--(BUSINESS WIRE)--Ra Medical Systems announces definitive merger agreement with Precision Catheter.

Ra Medical Systems Enters Into Definitive Merger Agreement with Catheter Precision

New York, New York--(Newsfile Corp. - September 11, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the stock of Medtronic plc (NYSE: MDT) between June 8, 2019 and May 25, 2022, both dates inclusive (the "Class Period"). If you wish to serve as lead plaintiff, you must move the Court no later than November 7, 2022.

ROSEN, A GLOBALLY RECOGNIZED FIRM, Encourages Medtronic plc Investors to Secure Counsel Before Important Deadline in Securities Class Action - MDT

AbbVie

Amcor Plc

Air Products and Chemicals

Franklin Resources

Caterpillar

Federal Realty Investment Trust

Leggett & Platt

Realty Income Corp

Stanley Black & Decker

T. Rowe Price Group

V.F.

Walgreens

"Dividend Aristocrats in the S&P 500 Index have raised their annual payouts every year for at least 25 consecutive years. "--Kiplinger.com/Investing. 65 Aristocrats screened as of September 8, 2022 represented all eleven Morningstar Sectors. Broker estimated-top-ten net-gains ranged 16.54%-36.34% topped by VFC & SWK.

4 S&P 500 Dividend Aristocrat Dogs To Buy, 1 To Watch

NEW YORK--(BUSINESS WIRE)-- #Action--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Medtronic PLC (“Medtronic” or the “Company”) (NYSE: MDT) in the United States District Court for the District of Minnesota on behalf of all persons and entities who purchased or otherwise acquired Medtronic securities between June 8, 2019 and May 25, 2022, both dates inclusive (the “Class Period”). Investors have until Nove

MEDTRONIC ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Medtronic PLC and Encourages Investors to Contact the Firm

SAN DIEGO--(BUSINESS WIRE)---- $MDT #MDT--Medtronic PLC (MDT) Had Inadequate Quality Control Systems that Delayed the Approval of its MiniMed 780G Device Causing Shareholders Financial Harm

News for Medtronic Stock (MDT)